Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Below 50 Day Moving Average – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $47.17 and traded as low as $45.53. Collegium Pharmaceutical shares last traded at $46.10, with a volume of 212,736 shares changing hands.

Analyst Ratings Changes

A number of brokerages have recently commented on COLL. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Needham & Company LLC upped their price target on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, Barclays cut their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $53.40.

Collegium Pharmaceutical Stock Performance

The company’s fifty day simple moving average is $47.17 and its 200 day simple moving average is $41.49. The stock has a market capitalization of $1.46 billion, a P/E ratio of 28.63 and a beta of 0.64. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares in the company, valued at approximately $2,475,141.87. The trade was a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently bought and sold shares of COLL. Massachusetts Financial Services Co. MA increased its stake in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after purchasing an additional 518,721 shares during the period. Millennium Management LLC grew its holdings in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Collegium Pharmaceutical by 161.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after buying an additional 316,109 shares during the period. Two Sigma Investments LP raised its holdings in Collegium Pharmaceutical by 897.2% during the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after buying an additional 242,310 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in Collegium Pharmaceutical by 237.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock valued at $11,216,000 after buying an additional 225,679 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.